Ms. Julia Becker reports

TEMPRAMED TECHNOLOGIES LTD. ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Further to the Sept. 23, 2026, and Sept. 28, 2026, news releases, Tempramed Technologies Ltd. has closed its non-brokered private placement of unsecured convertible debentures of the company and units. The company issued $600,000 of principal amount of convertible debentures and 1,155,880 units under the offering for gross aggregate proceeds of $1,177,940.

Each unit issued under the offering consists of one common share in the capital of the company and one common share purchase warrant of the company. Each warrant will entitle the holder thereof to purchase one additional common share at a price of $1 at any time on or before March 30, 2028.

The convertible debentures issued under the offering bear interest at a rate of 10 per cent per annum, calculated monthly and payable quarterly in cash. The convertible debentures issued under of the offering will mature on Sept. 30, 2027. The outstanding principal amount owed under each convertible debenture may be converted into common shares at a conversion price of 50 cents per common share by the holder thereof at any time on or before the maturity date.

The use of proceeds from the offering will finance new inventory and product development and scale the sales and marketing division globally, as well as finance general working capital.

In connection with the offering, the company paid an aggregate of $40,456 in finders' fees to certain qualified arm's-length parties, as well as issuing 80,912 common shares to such finders.

All securities issued in connection with the offering, including any warrant shares, are subject to a restricted period of four months and one day from closing of the offering.

About Tempramed Technologies Ltd.

Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered thermal insulation devices that work 24-seven without batteries or external power. With a product line already in market including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed continues to expand globally with solutions for medication protection and adherence.

We seek Safe Harbor.